Clinical Trial Goal
To find out if the combination of pirtobrutinib and rituximab is safe and works well to treat MZL that has not yet been treated
You may be able to join this trial if you:
- Are 18 years old or older
- Have MZL that has not yet been treated
- Do not have lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Pirtobrutinib is a small molecule inhibitor that blocks BTK in certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get:
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get:
- Pirtobrutinib – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Rituximab – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 7 years.
The Food and Drug Administration (FDA) has approved pirtobrutinib to treat chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) that has come back (relapsed) or not gotten better with treatment (refractory), or small lymphocytic lymphoma (SLL). The FDA has approved rituximab to treat MZL. Using them in this combination to treat newly diagnosed MZL is new and unproven.
Contacts
Rachel Kingsford, 801-585-0115, rachel.kingsford@hci.utah.edu
Narendranath Epperla, MD, MS, 801-585-0255, naren.epperla@hci.utah.edu
Locations
Washington UniversityRECRUITING
St Louis, Missouri
Anne Fischer, 314-362-3021, afischer@wustl.edu
Huntsman Cancer Institute at University of UtahRECRUITING
Salt Lake City, Utah
Rachel Kingsford, 801-585-0115, rachel.kingsford@hci.utah.edu
Sponsors
collaborator: Eli Lilly and Company, lead: University of Utah
